SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceXs strong Q3 results and outlook for expanding its AI-compute business, reinforced by a wave of analyst upgrades, are driving the rally. Bulls also point to possible Tesla merger discussions, while skeptics question the valuation and capital spending and flag a major share unlock as a potential source of selling pressure.

Strive, Inc. engages in the provision of an asset management Bitcoin treasury. It is focused on maximizing value for shareholders, accumulating bitcoin and outperforming bitcoin over the long run. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani, and Kyle Fairbanks on March 9, 2022 and is headquartered in Dallas, TX.

Strive Inc. - Ordinary Shares - Class A

Strive Inc.

Strives upsized SATS preferred-stock offering and its use to finance further Bitcoin accumulation are driving discussion, alongside reports of additional BTC purchases. Bulls see the preferred funding and growing treasury as supportive, while skeptics warn that the high dividend obligations and senior claims could weigh on common shareholders.

Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company was founded on June 3, 2024 is headquartered in New York, NY.

Skydance Corp. - Ordinary Shares - Class B

Skydances distribution of separately traded warrants has dominated discussion, as the shares fell sharply on the ex-warrant date and many traders debated how much of the move reflected the mechanical separation versus additional selling and confusion over broker handling. Reactions are split between holders who view the combined shares-and-warrants value as largely intact and skeptics focused on the companys heavy debt and dilution risk.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix shares are under pressure after softer next-quarter guidance and a reduced advertising outlook overshadowed an earnings beat, with analyst downgrades and target cuts adding to concerns about slowing growth and competition. Traders are divided between viewing the selloff as an overreaction and buying the dip, or expecting further weakness amid doubts about the companys growth prospects.

Icahn Enterprises LP is a holding company. It operates through the following segments: Investment, Automotive, Energy, Food Packaging, Real Estate, Home Fashion, Pharma, and Holding Company. The Investment segment consists of various private investment funds. The Automotive segment holds ownership in Icahn Automotive Group, LLC. The Energy segment refers to petroleum refining and marketing businesses. The Food Packaging segment involves the production and sale of cellulosic, fibrous, and plastic casings for the processed meat and poultry industry. The Real Estate segment offers rental real estate, property development, and resort activities. The Home Fashion segment deals with manufacturing, sourcing, marketing, distributing, and selling home fashion consumer products. The Pharma segments operate through Vivus, Inc., a specialized pharmaceutical company. The Holding Company segment manages acquisition and investment in operating businesses. The company was founded on February 17, 1987 and is headquartered in Sunny Isles Beach, FL.

Icahn Enterprises L P - Unit

Icahn Enterprises, L.P.

IEPs steep decline and new lows are driving discussion, with investors questioning the sustainability of its distribution amid losses, dilution and concerns about Icahn Enterprises performance. Bulls point to the value of its CVR Energy stake and high short interest as potential supports, while skeptics argue those factors have yet to offset the partnerships broader weakness.

JD.com, Inc. is a technology-driven E-commerce company, which engages in the sale of electronics products and general merchandise products, including audio, video products, and books. It operates in the following segments: JD Retail, JD Logistics, and New Businesses. The JD Retail segment offers online retail, online marketplace, and marketing services. The JD Logistics segment includes internal and external logistics businesses. The New Businesses segment is composed of JD Property, Jingxi, overseas businesses and technology initiatives. The company was founded on June 18, 1998, by Qiang Dong Liu and is headquartered in Beijing, China.

JD.com Inc - ADR

JDs quarterly results and the sharp selloff that followed dominate discussion, despite some traders viewing profitability and cash-flow trends as encouraging. The debate centers on whether weaker revenue reflects soft Chinese consumer demand and justifies the decline, or whether the market is overlooking improving margins and shareholder returns.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Metas quarterly earnings are the main focus, especially whether AI spending will keep rising and whether Muse and AI investments can support growth. Bullish traders expect strong AI and advertising momentum, while skeptics worry about heavy capital spending, pressure on cash flow, and a negative reaction even if results are solid.

Six Flags Entertainment Corp. engages in operating amusement parks in North America. It operates amusement parks, water parks, and resorts. The company is headquartered in Charlotte, NC.

Six Flags Entertainment Corp.

Six Flags Entertainment Corp

A fatal rider accident at Six Flags Over Georgia, followed by precautionary coaster closures as the investigation continues, is driving concern about safety, attendance and potential legal exposure. Traders are also weighing analyst target cuts and the companys heavy debt against hopes the incidents impact will fade and the business can recover.

United Airlines Holdings, Inc. is a holding company, which engages in the provision of transportation services. It operates through the following geographical segments: Domestic, Atlantic, Pacific, and Latin America. The company was founded on December 30, 1968 and is headquartered in Chicago, IL.

United Airlines Holdings Inc

Uniteds third-quarter results included a slight earnings miss and a much weaker fourth-quarter profit outlook, with elevated jet-fuel costs pressuring margins. Shares rebounded as traders focused on record revenue and resilient travel demand, though the community remains divided over whether higher fares can offset fuel costs.

Lam Research Corp. engages in the design, manufacture, marketing, refurbishment, and provision of semiconductor processing equipment used in the fabrication of integrated circuits. It operates through the following geographical segments: United States, China, Europe, Japan, Korea, Southeast Asia, and Taiwan. The company was founded by David K. Lam in 1980 and is headquartered in Fremont, CA.

Lam Research Corp.

Lam Researchs upcoming earnings report is the main focus, with traders watching guidance and semiconductor-equipment demand tied to AI and memory spending. Some see the recent selloff as an oversold buying opportunity, while others warn that high expectations and broader semiconductor weakness could weigh on the reaction.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Is Most-Watched Stock Johnson & Johnson (JNJ) Worth Betting on Now?

Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Healthcare ETFs to Buy as JNJ Slips 6% Despite Q3 Earnings Beat 

Johnson & Johnson's Q3 earnings beat fails to prevent a 6% stock drop, but three healthcare ETFs offer diversified exposure to its growth potential. 

The Zacks Analyst Blog Highlights Abbott Laboratories, Johnson & Johnson, Stryker, Waste Management and Republic Services

Healthcare and waste management offer long-term demand opportunities beyond AI in 2027, with Abbott Laboratories, Johnson & Johnson, Stryker, Waste Management and Republic Services in focus.

Johnson & Johnson Launches Next-Generation Shockwave C2 Aero Fly Coronary IVL Catheter, Cutting IVL Treatment Time in Half

Johnson & Johnson (NYSE: JNJ) announced today the U.S. launch of its Shockwave C2 Aero Fly Coronary IVL Catheter designed to treat a broad range of calcified coronary artery lesions in half the time as previous coronary IVL devices.1 Leveraging Shockwave IVLs differentiated mechanism of action, and...

Stryker Enters Soft-Tissue Robotics With $400 Million CMR Deal

SYK's $400 million investment in CMR Surgical marks its entry into soft-tissue robotics, expanding its surgical portfolio with Versius technology.

AbbVie's Neuroscience Franchise: What to Expect Ahead of Q3 Results

ABBV's neuroscience franchise targets nearly 16% revenue growth in Q3, with established drugs and newer Parkinson's therapies driving expansion.

Johnson & Johnson announces new data showing TREMFYA (guselkumab) is the only IL-23 to deliver durable fistula remission through 48 weeks in Crohn's disease with perianal fistula

Johnson & Johnson announces new data showing TREMFYA (guselkumab) is the only IL-23 to deliver durable fistula remission through 48 weeks in Crohn's disease with perianal fistula Johnson & Johnson announces new data showing TREMFYA (guselkumab) is the only IL-23 to deliver durable fistula remission...

JNJ Investors with $100,000 in Losses Have Opportunity to Join Johnson & Johnson Fraud Investigation with SBS Law

Schall, Brown & Schwartz LLP (SBS), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Johnson & Johnson (Johnson & Johnson or the Company) (NYSE: JNJ) for violations of the securities laws. INVESTIGATION DETAILS: The investigation...

Johnson & Johnson Just Raised Its Sales Outlook Again. Here's Why the Dividend King Is Still a Buy.

Key PointsPharmaceutical outfit Johnson & Johnson recently reported solid overall Q3 numbers with one alarming red flag...

Forget AI Stocks: Buy Med-Tech Stock ISRG Now for 40% Upside 

Intuitive Surgical stock earns a Zacks Rank #2 (Buy) and looks poised for a potential technical breakout as it overtakes vital long-term levels heading into its Q3 earnings release on October 20.

Johnson & Johnson raised 2026 estimated reported sales guidance to $101B$101.4B, with midpoint $101.2B, and adjusted EPS guidance to $11.05$11.15, midpoint $11.10, or 7.4% and 2.9% at midpoint.

Johnson & Johnsons adjusted EPS and adjusted net earnings declined; STELARA, SIMPONI/SIMPONI ARIA, and REMICADE partially offset Innovative Medicine growth; reported net earnings were $210M and EPS reflected a one-time talc litigation charge.

Johnson & Johnson raised 2026 sales and adjusted EPS guidance; OTTAVA received U.S. FDA market authorization and IMAAVY approval; Innovative Medicine operational sales grew 7.9% with named products among its growth drivers.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Johnson & Johnson

SLS, IBRX Rise Premarket: Funds Raise Their Bets As J&J Stays ‘On The Lookout’ For Deals

Equity

Neutral Sentiment

<ul class="summary-bullets"><li>Gamma Investing increased its Sellas stake by 293%, while Courier Capital doubled its ImmunityBio holding to about $1.06 million.</li><li>Everhart reported a $2.96 million Sellas position, while Hennion &amp; Walsh held $3.67 million in ImmunityBio.</li><li>J&amp;J’s Inlexzo generated over $90 million in quarterly sales, providing a competitive benchmark for ImmunityBio.</li></ul>Shares of Sellas Life Sciences (SLS) and ImmunityBio (IBRX) edged higher premarket on Wednesday as investors weighed fresh ownership disclosures alongside Johnson &amp; Johnson’s plans to strengthen its cancer-drug business through strategic deals.<a href="https://stocktwits.com/symbol/SLS">SLS stock</a> gained about 0.8% in premarket trading, while&nbsp;<a href="https://stocktwits.com/symbol/IBRX">IBRX</a> rose 0.3%.&nbsp;<h2 class="st-heading-2">Fresh Filings Reveal Bigger Bets On SLS And IBRX</h2>Recent ownership disclosures showed several investors increasing their positions in both companies for the quarter ended Sept. 30. In Sellas, Everhart Financial Group reported 240,213 shares valued at about $2.96 million. Independent Financial Group increased its holding by 3% to 24,000 shares worth $295,440.Gamma Investing raised its SLS stake by 293% to 2,186 shares. Financial Designs moved in the opposite direction, cutting its position by 17.75% to 19,186 shares valued at $236,180.In ImmunityBio, Courier Capital doubled its stake to 112,000 shares worth $1.06 million, adding 56,000 shares. Hennion &amp; Walsh Asset Management increased its holding by 1.45% to 409,749 shares valued at about $3.67 million. B. Riley Wealth Advisors reported an unchanged IBRX stake of 113,000 shares worth $1.07 million.<h2 class="st-heading-2">J&amp;J Outlines Deal Strategy As It Expands Cancer Business&nbsp;</h2>J&amp;J CFO Joe Wolk said that the company is interested in assets that could complement its business. “We always are on the lookout for strategic drivers that could complement our business that makes sense to be in our hands versus where the asset would currently reside, but also creates value for the risk we are bearing on behalf of shareholders,” Wolk said during the call.J&amp;J has already expanded its cancer pipeline through its $1 billion cash acquisition of Firefly Bio, completed in July. The deal added tech designed to deliver protein-degrading treatments directly to cancer cells, including those driven by KRAS mutations.CEO Joaquin Duato outlined the company’s broader goal: “Our ambition is to become the number one oncology company by 2030, with sales projected to exceed $50 billion,” he said. J&amp;J ended the quarter with $17 billion in cash and marketable securities against about $45 billion in debt. It generated over $6 billion in quarterly free cash flow and maintained its full-year forecast of $21 billion.Wolk nevertheless clarified that J&amp;J’s forecast for double-digit growth by the end of the decade rests on internal investments rather than future acquisitions. “It does not assume any inorganic additions at this moment in time,” he said.The call also gave a competitive update for ImmunityBio investors. Tom Cavanaugh, J&amp;J’s worldwide chairman of Innovative Medicine, said bladder-cancer treatment Inlexzo generated more than $90 million in third-quarter sales, with new patient inserts rising 45% from the previous quarter. The firm said it sees a sales opportunity exceeding $5 billion for the broader platform as it pursues additional patient populations.<h2 class="st-heading-2">SLS And IBRX Catalyst Watch</h2>Sellas is awaiting the final analysis of its Phase 3 Regal trial, which tests cancer-vaccine candidate Galinpepimut-S in acute myeloid leukemia (AML) patients in second complete remission. The analysis requires 80 deaths, up from the last reported 78, and will be followed by data verification before results are released.&nbsp;Meanwhile, initial Phase 2 results for SLS009, also called Tambiciclib, in newly diagnosed AML patients are expected in the fourth quarter.&nbsp;ImmunityBio is focused on expanding Anktiva’s reach. The immunotherapy is approved or authorized across 34 countries, and second-quarter net product revenue rose 92% year-over-year to $50.7 million. A Food and Drug Administration (FDA) decision is expected by Jan. 6, 2027, on expanding Anktiva plus Bacillus Calmette-Guérin (BCG) to patients with BCG-unresponsive bladder cancer involving papillary tumors without carcinoma in situ.<h2 class="st-heading-2">How Do Retail Traders Feel About SLS And IBRX?</h2>On Stocktwits, SLS sentiment was 'bearish' amid 'high' message volume, while IBRX sentiment was 'neutral' amid 'low' message volume.&nbsp;“Guys it’s a sign. JnJ locked in!” one SLS user&nbsp;<a href="https://stocktwits.com/Biobanker/message/666423145">said</a>. Another&nbsp;<a href="https://stocktwits.com/7is7/message/666437906">asked</a>, “When would the buyout be?”<stembedurl>https://stocktwits.com/7is7/message/666437906</stembedurl>On ImmunityBio’s feed, discussion of J&amp;J focused on rival Inlexzo. One user&nbsp;<a href="https://stocktwits.com/bike_it_59/message/666391216">questioned</a> whether J&amp;J had disclosed the drug’s sales and cited analyst estimates around $70 million.&nbsp;<stembedurl>https://stocktwits.com/bike_it_59/message/666391216</stembedurl>So far this year, IBRX has surged 395%, while SLS has gained 229%.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/spacex-worth-50-trillion-10-years-ron-baron-elon-thinks-im-way-low/cZxfiwQRBpg">SpaceX Could Be Worth $50 Trillion In 10 Years, Says Ron Baron: ‘Elon Thinks I’m Way Low’&nbsp;</a>

In this photo illustration, a Johnson & Johnson logo seen displayed on a monitor. (Photo Illustration by Valera Golovniov/SOPA Images/LightRocket via Getty Images)

J&J is open to strategic acquisitions and targets more than $50 billion in oncology sales by 2030.

ImmunityBio Inc

SELLAS Life Sciences Group Inc

SPDR S&P Biotech ETF

Health Care Select Sector SPDR Fund

Double beat (rev + EPS)

Revenue beat, EPS miss

EPS beat, revenue miss

Double miss

Meta ($META) reports earnings after the close today. What do you expect?

Stocktwits

) reports earnings after the close today. What do you expect?

Current Price	$255.92
Prev Close	$259.36
Open	$258.20
Dividend Yield	2.48%
50-Day Moving Average	$265.07
Beta	-0.01
Avg. Volume	6.3M
PE Ratio	39.34

52-Week High	$281.07
52-Week Low	$184.66
Market Capitalization	$625.03B
EPS (Annual)	$11.03
Price to Book	7.35
Revenue Per Employee	$668,877.84

Feed

News

Sentiment

Earnings

NewFutures

Fundamentals

Info

JNJ Fundamentals